文献速递妇产影像US

低风险人群中孕20周起胎儿生长轨迹对严重不良围产结局的预测价值:IRIS研究二次分析

Predictive value of fetal growth trajectory from 20 weeks of gestation onwards for severe adverse perinatal outcome in low-risk population: secondary analysis of IRIS study.
PubMed 文献 · Ultrasound Obstet Gynecol · 2023-01-01

该研究为IRIS试验的事后分析,纳入6296例低风险单胎妊娠,评估18+0至23+6周与32+0至36+6周间胎儿生长轨迹对严重不良围产结局(SAPO)的预测价值。结果显示,单独的生长轨迹减慢指标与SAPO风险升高无关;但32+0至36+6周EFW<p10合并EFW下降>20百分位、或AC/EFW<p10合并ACGV<p10与SAPO风险升高相关。结论认为单独生长轨迹标准不足以区分FGR与体质性小胎儿。

要点

  • 单独AC或EFW下降>20或>50百分位、或ACGV<p10与SAPO风险升高无关。
  • 32+0至36+6周EFW<p10合并EFW下降>20百分位与SAPO风险升高相关。
  • 32+0至36+6周AC或EFW<p10合并ACGV<p10与SAPO风险升高相关。

核心结论

  • 在低风险人群中,单独以胎儿生长轨迹减慢为标准不能充分区分FGR与体质性小胎儿;这种无关联可能源于诊断不准确和/或诊断后(如干预和选择)偏倚。作者认为,检测胎盘功能不全的新方法应整合母血清生物标志物和多普勒超声测量等诊断工具的信息。

研究设计与样本

  • IRIS研究(荷兰全国性整群随机试验)的事后数据分析,纳入6296例低风险单胎妊娠;第一次超声为18+0至23+6周常规畸形筛查,第二次为32+0至36+6周;采用多水平logistic回归分析。

诊断标准与关键数值

  • 生长轨迹减慢定义为AC和/或EFW下降超过20百分位或超过50百分位,或ACGV<第10百分位(p10);SGA定义为32+0至36+6周AC或EFW<p10;严重SGA定义为AC/EFW<第3百分位。

临床应用与阅片要点

  • 原文结论未据此给出推荐;作者认为检测胎盘功能不全的新方法应整合母血清生物标志物和多普勒超声测量等信息。

局限性

  • 原文指出这种无关联可能源于诊断不准确和/或诊断后(如干预和选择)偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: The placental dysfunction underlying fetal growth restriction (FGR) may result in severe adverse perinatal outcome (SAPO) related to fetal hypoxia. Traditionally, the diagnostic criteria for FGR have been based on fetal size, an approach that is inherently flawed because it often results in either over- or underdiagnosis. The anomaly ultrasound scan at 20 weeks' gestation may be an appropriate time at which to set a benchmark for growth potential of the individual fetus. We hypothesized that the fetal growth trajectory from that point onwards may be informative regarding third-trimester placental dysfunction. The aim of this study was to investigate the predictive value for SAPO of a slow fetal growth trajectory between 18 + 0 to 23 + 6 weeks and 32 + 0 to 36 + 6 weeks' gestation in a large, low-risk population.

METHODS: This was a post-hoc data analysis of the IUGR Risk Selection (IRIS) study, a Dutch nationwide cluster-randomized trial assessing the (cost-)effectiveness of routine third-trimester sonography in reducing SAPO. In the current analysis, for the first ultrasound examination we used ultrasound data from the routine anomaly scan at 18 + 0 to 23 + 6 weeks' gestation, and for the second we used data from an ultrasound examination performed between 32 + 0 and 36 + 6 weeks' gestation. Using multilevel logistic regression, we analyzed whether SAPO was predicted by a slow fetal growth trajectory, which was defined as a decline in abdominal circumference (AC) and/or estimated fetal weight (EFW) of more than 20 percentiles or more than 50 percentiles or as an AC growth velocity (ACGV) < 10th percentile (p10). In addition, we analyzed the combination of these indicators of slow fetal growth with small-for-gestational age (SGA) (AC or EFW < p10) and severe SGA (AC/EFW < 3rd percentile) at 32 + 0 to 36 + 6 weeks' gestation.

RESULTS: Our sample included the data of 6296 low-risk singleton pregnancies, among which 82 (1.3%) newborns experienced at least one SAPO. Standalone declines in AC or EFW of > 20 or > 50 percentiles or ACGV < p10 were not associated with increased odds of SAPO. EFW < p10 between 32 + 0 and 36 + 6 weeks' gestation combined with a decline in EFW of > 20 percentiles was associated with an increased rate of SAPO. The combination of AC or EFW < p10 between 32 + 0 and 36 + 6 weeks' gestation with ACGV < p10 was also associated with increased odds of SAPO. The odds ratios of these associations were higher if the neonate was SGA at birth.

CONCLUSIONS: In a low-risk population, a slow fetal growth trajectory as a standalone criterion does not distinguish adequately between fetuses with FGR and those that are constitutionally small. This absence of association may be a result of diagnostic inaccuracies and/or post-diagnostic (e.g. intervention and selection) biases. We conclude that new approaches to detect placental insufficiency should integrate information from diagnostic tools such as maternal serum biomarkers and Doppler ultrasound measurements. © 2023 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.

来源:Ultrasound Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Kamphof HD, van Roekel M, Henrichs J, et al. Predictive value of fetal growth trajectory from 20 weeks of gestation onwards for severe adverse perinatal outcome in low-risk population: secondary analysis of IRIS study. Ultrasound Obstet Gynecol. 2023. PMID: 37204332. doi:10.1002/uog.26250

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。